IMP-3 is differentially expressed in normal and neoplastic lymphoid tissue
Authors:
- Rebecca L. KingRKRebecca L. King
- Theresa PashaTPTheresa Pasha
- Michele R. RoulletMRMichele R. Roullet
- Paul J. ZhangPZPaul J. Zhang
- Adam BaggABAdam Bagg
- 1 December 2009
- journal article
- Published by Elsevier in Human Pathology
- Vol. 40 (12) , 1699-1705
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- RNA‐binding protein insulin‐like growth factor II mRNA‐binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma†Hepatology, 2008
- Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's LymphomaNew England Journal of Medicine, 2008
- Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumorsHuman Pathology, 2008
- Oncofetal protein IMP3Cancer, 2008
- External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinomaCancer, 2008
- Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlationsLaboratory Investigation, 2007
- IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16INK4a expressionLaboratory Investigation, 2007
- Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and testicular cancerReproduction, 2005
- Expression of the highly conserved RNA binding protein KOC in embryogenesisMechanisms of Development, 1999
- A Family of Insulin-Like Growth Factor II mRNA-Binding Proteins Represses Translation in Late DevelopmentMolecular and Cellular Biology, 1999